Toprol-XL


Also found in: Thesaurus, Medical, Wikipedia.
Related to Toprol-XL: metoprolol, Metoprolol succinate

Top·rol-XL

 (tŏp′rôl′, -rŏl′)
A trademark for an extended-release formulation of the succinate salt of metoprolol.
References in periodicals archive ?
patient cohort of 127 patients, a trend for potential superior benefit in favor of Gencaro over TOPROL-XL was observed with a PPoS of 61%, which was greater than the prespecified criteria set by the company to proceed to Phase 3 development.
M2 EQUITYBITES-November 30, 2017-Lannett grants the distribution rights for authorized generic version of Toprol-XL to Aralez Pharmaceuticals
M2 PHARMA-November 30, 2017-Lannett grants the distribution rights for authorized generic version of Toprol-XL to Aralez Pharmaceuticals
for the rights to branded and approved generic Toprol-XL (metoprolol succinate) in the US.
NASDAQ: ARLZ) (TSX: ARZ) will acquire the US rights to Toprol-XL (metoprolol succinate) and its authorised generic pursuant to an agreement between UK-based pharmaceutical developer AstraZeneca plc and Ireland-based legal activities company Aralez Pharmaceuticals Trading DAC, a subsidiary of Aralez, the company said.
The DoJ has required documents regarding the companies' cooperation over widely used acid reflux medicines Nexium and Prilosec as well as blood-pressure drugs Plendil and Toprol-XL, according to AstraZeneca.
The company's sales and profits have been hurt by competition from generic versions of its drugs, including the blood-pressure treatment Toprol-XL and the asthma drug Pulmicort Respules.
Generic competition for Pulmicort Respules for asthma and Toprol-XL blood-pressure treatment also hurt sales.
Astra also reassured in its last statement that it was benefiting from the withdrawal of generic products for Toprol-XL.
8billion in the quarter, with non-US business offsetting flat growth in America after their high blood pressure treatment Toprol-XL was hit by cheaper generic rivals.
78bn in the quarter, with non-US business offsetting flat growth in America after its high blood pressure treatment Toprol-XL was hit by competition from cheaper generic rivals.
Sales of Toprol-XL, a treatment for angina, heart failure and high blood pressure, dived 43% in the third quarter, after generic competition launched in August.